Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics' Q4 Revenues Increase 134 Percent on PGx Test Sales

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Genetics has reported a 134 percent increase in its fourth-quarter revenues, driven by sales of its ResponseDx line of pharmacogenomic tests.

The Los Angeles-based firm brought in total revenues of $3.4 million for the three-month period ended Dec. 31 compared to $1.4 million for the fourth quarter of 2008. The company cited a ramp up in sales of its ResponseDx tests, with revenues growing 81 percent compared to the third quarter of 2009.

Response Genetics' net loss for the quarter was halved to $1.7 million, or $.11 per share, from $3.4 million, or $.33 per share.

Its R&D spending increased to $559,080 from $433,044 year over year, and its SG&A spending increased to $2.7 million from $2.2 million.

For full-year 2009, Response Genetics' sales rose 28 percent to $9.1 million from $7.1 million.

Its net loss dropped to $9.3 million, or $.70 per share, from $9.5 million, or $.93 per share. The firm's R&D expenses increased to $2.3 million from $2.1 million, while its SG&A spending jumped to $9.7 million from $7.5 million.

Response Genetics finished the year with cash and cash equivalents of $7.1 million.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.